Drug intelligence / Profile preview

masofermin

Development stage: Preclinical
Lead developer: ESSA Pharma
Modality: Small Molecules

Overview

Masofermin is a clinical-stage small molecule developed by ESSA Pharma for the treatment of prostate cancer. It was identified as the lead asset of ESSA Pharma prior to the company's acquisition by XenoTherapeutics.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on masofermin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on masofermin.

Explore the full profile